JP2004529901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529901A5 JP2004529901A5 JP2002569842A JP2002569842A JP2004529901A5 JP 2004529901 A5 JP2004529901 A5 JP 2004529901A5 JP 2002569842 A JP2002569842 A JP 2002569842A JP 2002569842 A JP2002569842 A JP 2002569842A JP 2004529901 A5 JP2004529901 A5 JP 2004529901A5
- Authority
- JP
- Japan
- Prior art keywords
- diazabicyclo
- heptane
- group
- quinolinyl
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UKHJNJFJCGBKSF-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.1]heptane Chemical class C1NC2CNC1C2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- -1 2-quinolinyl group Chemical group 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010008874 Chronic fatigue syndrome Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- UXWOEDPLDSDOAV-IUCAKERBSA-N 2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,3-benzothiazole Chemical compound C1=CC=C2SC(N3C[C@]4(NC[C@]3([H])C4)[H])=NC2=C1 UXWOEDPLDSDOAV-IUCAKERBSA-N 0.000 claims 1
- SKRHVLRIOAWBKF-JQWIXIFHSA-N 2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-6-nitroquinoline Chemical compound C1=C([N+]([O-])=O)C=CC2=NC(N3C[C@]4(NC[C@]3([H])C4)[H])=CC=C21 SKRHVLRIOAWBKF-JQWIXIFHSA-N 0.000 claims 1
- RZMWGSCJGCKAGD-RYUDHWBXSA-N 2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinoline Chemical compound C1=CC=CC2=NC(N3C[C@]4(NC[C@]3([H])C4)[H])=CC=C21 RZMWGSCJGCKAGD-RYUDHWBXSA-N 0.000 claims 1
- ADUMJOKDBFNXAV-UWVGGRQHSA-N 2-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,3-benzothiazole Chemical compound C1=CC=C2SC(N3C[C@]4(N(C[C@]3([H])C4)C)[H])=NC2=C1 ADUMJOKDBFNXAV-UWVGGRQHSA-N 0.000 claims 1
- DJECVQJISRCJAC-STQMWFEESA-N 2-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-6-nitroquinoline Chemical compound C1=C([N+]([O-])=O)C=CC2=NC(N3C[C@]4(N(C[C@]3([H])C4)C)[H])=CC=C21 DJECVQJISRCJAC-STQMWFEESA-N 0.000 claims 1
- DJWFGHSFBAXWJS-STQMWFEESA-N 2-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-6-amine Chemical compound C1=C(N)C=CC2=NC(N3C[C@]4(N(C[C@]3([H])C4)C)[H])=CC=C21 DJWFGHSFBAXWJS-STQMWFEESA-N 0.000 claims 1
- XZDDYBKLXPTCCB-STQMWFEESA-N 2-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinoline Chemical compound C1=CC=CC2=NC(N3C[C@]4(N(C[C@]3([H])C4)C)[H])=CC=C21 XZDDYBKLXPTCCB-STQMWFEESA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 206010004939 Bipolar I disease Diseases 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 206010009191 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000001187 Dyskinesias Diseases 0.000 claims 1
- 206010013932 Dyslexia Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 206010028403 Mutism Diseases 0.000 claims 1
- GTCASOGIFFZWTG-GJZGRUSLSA-N N-[2-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-6-yl]acetamide Chemical compound C1=C(NC(C)=O)C=CC2=NC(N3C[C@]4(N(C[C@]3([H])C4)C)[H])=CC=C21 GTCASOGIFFZWTG-GJZGRUSLSA-N 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 206010033666 Panic disease Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 206010037999 Reading disease Diseases 0.000 claims 1
- 206010039911 Seizure Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 206010044126 Tourette's disease Diseases 0.000 claims 1
- 208000002271 Trichotillomania Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000002055 autistic disease Diseases 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000003111 delayed Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
Claims (5)
- R1 が水素又はC1-6- アルキル基を示す、請求項1記載の2,5−ジアザビシクロ[2.2.1]ヘプタン誘導体。
- 2−(2−キノリニル)−(1S,4S)−(+)−2,5−ジアザビシクロ−[2.2.1]−ヘプタン;
2−(2−キノリニル)−5−メチル−(1S,4S)−(+)−2,5−ジアザビシクロ−[2.2.1]−ヘプタン;
2−(6−ニトロ−2−キノリニル)−(1S,4S)−2,5−ジアザビシクロ−[2.2.1]−ヘプタン;
2−(6−ニトロ−2−キノリニル)−5−メチル−(1S,4S)−2,5−ジアザビシクロ−[2.2.1]−ヘプタン;
2−(6−アミノ−2−キノリニル)−5−メチル−(1S,4S)−2,5−ジアザビシクロ−[2.2.1]−ヘプタン;
2−(6−アセチルアミノ−2−キノリニル)−5−メチル−(1S,4S)−2,5−ジアザビシクロ−[2.2.1]−ヘプタン;
2−(2−ベンゾチアゾリル)−(1S,4S)−2,5−ジアザビシクロ−[2.2.1]−ヘプタン; 又は
2−(2−ベンゾチアゾリル)−5−メチル−(1S,4S)−2,5−ジアザビシクロ−[2.2.1]−ヘプタン;
又はそのあらゆる対掌体、その対掌体のあらゆる混合物、又はその薬学的に許容し得る塩である、請求項1記載の2,5−ジアザビシクロ[2.2.1]ヘプタン誘導体。 - 請求項1〜3のいずれかに1つに記載の2,5−ジアザビシクロ[2.2.1]ヘプタン誘導体又はそのあらゆる対掌体、その対掌体のあらゆる混合物、又はその薬学的に許容し得る塩の治療上有効な量を、少なくとも1種の薬学的に許容し得るキャリヤー又は希釈剤と共に含有する薬学的調合物。
- 請求項1〜3のいずれか1つに記載の2,5−ジアザビシクロ[2.2.1]ヘプタン誘導体又は請求項4記載の薬学的調合物を、不安、認知障害、学習欠陥、記憶−欠損又は機能障害、アルツハイマー病、注意欠陥、注意欠陥過活動性障害、パーキンソン病、ハンチングトン病、筋萎縮性側索硬化症、ジル・ド・ラ・ツレット症候群、うつ病、躁病、躁鬱病、統合失調症、強迫性障害(OCD)、パニック障害;神経性食欲不振、過食症及び肥満より群から選ばれる摂食障害、睡眠発作、侵害受容、AIDS−痴呆症、老人性痴呆症、パーフェリック (periferic)ニューロパシー, 自閉症、読書障害、遅発性ジスキネジー、運動亢進症、癲癇、過食症、外傷後症候群、ソーシャルホビア、慢性疲労症候群、睡眠障害、仮性痴呆、ガンザー症候群、月経前症候群、晩期黄体期症候群、慢性疲労症候群、無言症、トリコチロマニア又は時差ボケの治療、予防又は緩和用医薬の製造に使用する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200100344 | 2001-03-02 | ||
PCT/DK2002/000133 WO2002070522A1 (en) | 2001-03-02 | 2002-02-28 | Novel 2,5-diazabicyclo[2.2.1]heptane derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004529901A JP2004529901A (ja) | 2004-09-30 |
JP2004529901A5 true JP2004529901A5 (ja) | 2009-02-05 |
JP4294958B2 JP4294958B2 (ja) | 2009-07-15 |
Family
ID=8160337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002569842A Expired - Fee Related JP4294958B2 (ja) | 2001-03-02 | 2002-02-28 | 新規2,5−ジアザビシクロ[2.2.1]ヘプタン誘導体 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7329754B2 (ja) |
EP (1) | EP1368348B1 (ja) |
JP (1) | JP4294958B2 (ja) |
CN (1) | CN1331864C (ja) |
AT (1) | ATE287404T1 (ja) |
AU (1) | AU2002233181B2 (ja) |
CA (1) | CA2438815A1 (ja) |
DE (1) | DE60202667T2 (ja) |
DK (1) | DK1368348T3 (ja) |
HK (1) | HK1068878A1 (ja) |
MX (1) | MXPA03007895A (ja) |
NZ (1) | NZ527006A (ja) |
WO (1) | WO2002070522A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002352878B2 (en) * | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
CN101952278A (zh) * | 2008-02-15 | 2011-01-19 | 弗·哈夫曼-拉罗切有限公司 | 3-烷基-哌嗪衍生物及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN166416B (ja) * | 1985-09-18 | 1990-05-05 | Pfizer | |
US5196548A (en) | 1989-05-11 | 1993-03-23 | Pfizer Inc. | Preparation of diazabicyclic Intermediates |
JPH06228138A (ja) | 1993-02-03 | 1994-08-16 | Fujisawa Pharmaceut Co Ltd | ピリドシンノリン化合物またはその塩及びこれを含有する抗菌剤 |
US5478939A (en) * | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
US5561127A (en) | 1994-12-19 | 1996-10-01 | Allelix Biopharmaceuticals, Inc. | Muscarinic receptor ligands |
FR2786769B1 (fr) | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
DE60038823D1 (de) * | 1999-01-29 | 2008-06-19 | Abbott Lab | Diazabicycloderivate als Nikotin-Acetylcholin-Rezeptorliganden |
EP1289996B1 (en) | 2000-05-25 | 2005-04-06 | Targacept, Inc. | Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands |
US6552015B2 (en) | 2000-08-03 | 2003-04-22 | Pfizer Inc. | Azabicycloalkane derivatives and therapeutic uses thereof |
-
2002
- 2002-02-28 AU AU2002233181A patent/AU2002233181B2/en not_active Ceased
- 2002-02-28 DK DK02700189T patent/DK1368348T3/da active
- 2002-02-28 WO PCT/DK2002/000133 patent/WO2002070522A1/en active IP Right Grant
- 2002-02-28 US US10/250,765 patent/US7329754B2/en not_active Expired - Fee Related
- 2002-02-28 JP JP2002569842A patent/JP4294958B2/ja not_active Expired - Fee Related
- 2002-02-28 MX MXPA03007895A patent/MXPA03007895A/es active IP Right Grant
- 2002-02-28 AT AT02700189T patent/ATE287404T1/de not_active IP Right Cessation
- 2002-02-28 EP EP02700189A patent/EP1368348B1/en not_active Expired - Lifetime
- 2002-02-28 NZ NZ527006A patent/NZ527006A/en unknown
- 2002-02-28 CN CNB028050770A patent/CN1331864C/zh not_active Expired - Fee Related
- 2002-02-28 CA CA002438815A patent/CA2438815A1/en not_active Abandoned
- 2002-02-28 DE DE60202667T patent/DE60202667T2/de not_active Expired - Lifetime
-
2005
- 2005-02-16 HK HK05101237A patent/HK1068878A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005524713A5 (ja) | ||
CN1181074C (zh) | 制备三亚乙基二胺(teda)的方法 | |
JP2009538867A5 (ja) | ||
JP2005538187A5 (ja) | ||
JP2006508109A5 (ja) | ||
JP2010520265A5 (ja) | ||
JP2004527467A5 (ja) | ||
JP2009538870A5 (ja) | ||
ZA200609255B (en) | 1-aza--bicyclo[3.3.1] nonanes | |
JP2007530635A5 (ja) | ||
JP2009538869A5 (ja) | ||
JP2010520264A5 (ja) | ||
RU2005101748A (ru) | Новые хинуклидиновые производные и их применение | |
RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
JP2005530814A5 (ja) | ||
JP2009537599A5 (ja) | ||
JP2006519868A5 (ja) | ||
JP2004529901A5 (ja) | ||
JP2009526776A5 (ja) | ||
US7776880B2 (en) | Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | |
HUP0401207A2 (hu) | Emlősökben a kolinerg funkció módosítására szolgáló gyógyszerészeti készítmény és módszer | |
JP2006503062A5 (ja) | ||
JP2019501923A (ja) | 極性非プロトン性溶媒を用いたn−[4−(1−アミノエチル)−フェニル]−スルホンアミド誘導体のキラル分割方法 | |
AU769005B2 (en) | Method for the racemization of optically active amines | |
JP2009537598A5 (ja) |